Jose Pacheco, Principal Investigator at The START Center for Cancer Research, shared on LinkedIn:
“Antibody drug conjugates becoming options for small cell lung cancer, one has superior progression free and overall survival compared to topotecan in phase 3. May be a good option after tarlatamab or for those who can not get tarlatamab.”
Title: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
Authors: Yuanyuan Zhao, Hongxu Liu, Xiangjiao Meng, Zhihua Liu, Yan Yu, YulongZheng, Longhua Sun, Runxiang Yang, Jian Liu, Yanqiu Zhao, Lin Wu, Lei Yang, Zhiye Zhang, Mingjun Li, Peng Zhang, Yan Zhang, Hua Zhong, Jiuwei Cui, Zhangzhou Huang, Yanwei Yin, Manxiang Li, Fan Tong, Dan Xue, Dongqing Lv, Xufeng Li, Xian Zhang, Steve Chin, Jiaqiang Cai, Tongtong Xue, Yan Huang, Hongyun Zhao, Li Zhang.
Read the full article.
You can also read:
